We are live on ! Find out more
MRNS

Marinus Pharmaceuticals, Inc

Delisted

MRNS was delisted on the 10th of February, 2025.

21 hedge funds and large institutions have $52.8M invested in Marinus Pharmaceuticals, Inc in 2015 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 2

40% more funds holding

Funds holding: 1521 (+6)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

14% less capital invested

Capital invested by funds: $61.7M → $52.8M (-$8.85M)

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

Holders
21
Holders Change
+6
Holders Change %
+40%
% of All Funds
0.56%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
8
Increased
3
Reduced
5
Closed
2
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
CPV
1
Canaan Partners VII
Connecticut
$22.1M
Franklin Resources
2
Franklin Resources
California
$11M -$1.82M -41,500 -12%
NLVP
3
New Leaf Venture Partners
New York
$4.71M +$1.15M +26,216 +25%
EA
4
Emerald Advisers
Pennsylvania
$3.37M +$1.26M +28,781 +42%
PI
5
Putnam Investments
Massachusetts
$2.7M
AIC
6
AWM Investment Company
New York
$2.4M
SFM
7
Sphera Funds Management
Israel
$1.92M -$878K -20,000 -27%
BBA
8
Baker Bros. Advisors
New York
$1.8M -$49.1K -1,119 -2%
EMFAT
9
Emerald Mutual Fund Advisers Trust
Pennsylvania
$1.42M
ACP
10
Acuta Capital Partners
California
$325K +$396K +9,027 New
Morgan Stanley
11
Morgan Stanley
New York
$299K +$365K +8,322 New
Geode Capital Management
12
Geode Capital Management
Massachusetts
$189K +$231K +5,271 New
Goldman Sachs
13
Goldman Sachs
New York
$150K -$15.4K -351 -8%
SIM
14
Spark Investment Management
New York
$148K +$183K +4,175 New
HCM
15
Harvey Capital Management
Florida
$134K +$165K +3,750 New
WMSA
16
Weiss Multi-Strategy Advisers
New York
$90K +$110K +2,500 New
CGT
17
Capital Guardian Trust
California
$37K +$45.2K +1,030 New
BIT
18
BlackRock Institutional Trust
California
$14K +$17.4K +397 New
BIM
19
BlackRock Investment Management
Delaware
$9K +$1.01K +23 +10%
TRCT
20
Tower Research Capital (TRC)
New York
$3K -$39.6K -902 -92%
Manulife (Manufacturers Life Insurance)
21
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1
UOC
22
UBS O'Connor
Illinois
-$524K -12,425 Closed
Deutsche Bank
23
Deutsche Bank
Germany
-$2K -64 Closed

MRNS Hedge Fund Activity: Q1 2015 in Review

21 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q1 2015, worth a combined $52.8M — down 14% from $61.7M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new MRNS positions and 2 closed out — a net gain of 6 holders — while 3 added to existing stakes and 5 trimmed.

The largest buyer was Emerald Advisers, adding an estimated $1.26M. The largest seller was Franklin Resources, cutting an estimated $1.82M.

  • 21 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q1 2015, up from 15 in Q4 2014.
  • Funds reported $52.8M of Marinus Pharmaceuticals, Inc stock for Q1 2015, down 14% quarter-over-quarter.
  • 8 funds opened new Marinus Pharmaceuticals, Inc positions in Q1 2015 and 2 closed out, a net change of +6 holders.
  • The largest Marinus Pharmaceuticals, Inc buyer in Q1 2015 was Emerald Advisers, an estimated $1.26M added.
  • The largest Marinus Pharmaceuticals, Inc seller in Q1 2015 was Franklin Resources, an estimated $1.82M sold.

Based on aggregated 13F filings for Q1 2015.